2023
DOI: 10.1002/clt2.12315
|View full text |Cite
|
Sign up to set email alerts
|

A high‐dose, depigmented polymerized birch pollen extract for subcutaneous allergen immunotherapy has a favourable efficacy/safety ratio

Oliver Pfaar,
Angelika Sager,
Ralph Mösges
et al.

Abstract: BackgroundSubcutaneous allergen immunotherapy (SCIT) with depigmented, polymerized (DPP) birch pollen extract has been marketed at doses of up to 1000 DPP units/mL since 2001. We sought to determine the dose‐dependent efficacy of a DPP birch pollen extract formulation in patients suffering from birch‐pollen‐induced allergic rhinitis or rhinoconjunctivitis with or without intermittent asthma.MethodsA titrated conjunctival provocation test (CPT) was applied as a surrogate marker. This Phase II randomized, double… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 65 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?